GlassScriptPhysician profile
Apoorva Cheeti
NPI 1346703675
$989.88
in general payments reported to CMS, 2019-2025
15 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $239 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.91 |
| Education | $267.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $270.37 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $226.69 | 2024-2025 | Lynparza, Calquence, Imfinzi |
| Alexion Pharmaceuticals, INC. | $113.26 | 2025 | Soliris, Ultomiris |
| Merck Sharp & Dohme LLC | $84.65 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Glaxosmithkline, LLC. | $58.73 | 2024-2025 | Zejula, Jemperli |
| Astellas Pharma US INC | $47.12 | 2025 | Vyloy |
| Janssen Biotech, INC. | $35.77 | 2025 | Rybrevant |
| Jazz Pharmaceuticals INC. | $33.54 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.43 | 2025 | Libtayo |
| Eisai INC. | $19.85 | 2025 | |
| Incyte Corporation | $18.18 | 2025 | Monjuvi |
| Puma Biotechnology, INC. | $17.71 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $15.15 | 2025 | Libtayo |
| Sobi, INC | $13.78 | 2025 | |
| Pharmacosmos Therapeutics INC. | $13.65 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apoorva Cheeti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.